Renal cell protection of erythropoietin beyond correcting the anemia in chronic kidney disease patients

Cell Journal

Volumn 15, Issue 4, 2014, Pages 378-380

  Nasri, Hamid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Erythropoiesis; Erythropoietin

Indexed keywords

CREATININE; ERYTHROPOIETIN; NITROGEN; UREA;

ANEMIA; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; ERYTHROID PRECURSOR CELL; HUMAN; KIDNEY CELL; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LETTER; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

EID: 84891919861     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Letter

References (25)

1. Gianella P, Martin PY, Stucker F. Management of renal anemia in 2013. Rev Med Suisse. 2013; 9(375): 462-464, 466-467.
2. Nasri H. Association of serum leptin with anemia in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl. 2006; 17(4): 521-525.
3. Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int Suppl. 2007; (107): S21-25.
4. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012; 318(9): 1068-1073.
5. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23(10): 1631-1634.
6. Chang FC, Chou YH, Chen YT, Lin SL. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc. 2012; 111(11): 589-598.
7. Gobe GC, Morais C, Vesey DA, Johnson DW. Use of high-dose erythropoietin for repair after injury: a comparison of outcomes in heart and kidney. J Nephropathy. 2013; 2(3): 154-165.
8. Gheissari A. Acute kidney injury and renal angina. J Ren Inj Prev. 2013; 2(2): 33-34.
9. Kadkhodaee M. Erythropoietin; bright future and new hopes for an old drug. J Nephropathol. 2012; 1(2): 81-82.
10. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66(2): 753-760.
11. Gheshlaghi F. Toxic renal injury at a glance. J Ren Inj Prev. 2012; 1(1): 15-16.
12. Alhamad T, Blandon J, Meza AT, Bilbao JE, Hernandez GT. Acute kidney injury with oxalate deposition in a patient with a high anion gap metabolic acidosis and a normal osmolal gap. J Nephropathol. 2013; 2(2): 139-143.
13. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H, et al. Erythropoietin ameliorates gentamicin-induced renal toxicity: a biochemical and histopathological study. J Nephropathol. 2012; 1(2): 109-116.
14. Nematbakhsh M, Ashrafi F, PezeshkiZ, Fatahi Z, Kianpoor F, Sanei MH, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: which one is the first observation as side effect of cisplatin-induced toxicity in animal model. J Nephropathol. 2012; 1(3): 190-193.
15. Gheissari A, Hemmatzadeh S, Merrikhi A, Fadaei Tehrani S, Madihi Y. Chronic kidney disease in children: a report from a tertiary care center over 11 years. J Nephropathol. 2012; 1(3): 177-182.
16. Ghorbani A, Omidvar B, Parsi A. Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind controlled randomized clinical trial. J Nephropathol. 2013; 2(2): 129-134.
17. Nasri H. Acute kidney injury and beyond. J Ren Inj Prev. 2012; 1(1): 1-2.
18. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common betasubunit heteroreceptor. Proc Natl Acad Sci USA. 2004; 101: 14907-14912.
19. Sánchez-Niño MD, Ortiz A. Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?. J Nephropathol. 2012; 1(3): 152-154.
20. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications?. J Pharmacol ExpTher. 2007; 323(3): 759-762.
21. Maxwell PH, Ferguson DJ, Nicholls LG, Johnson MH, Ratcliffe PJ. The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int. 1997; 52(3): 715-724.
22. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011; 121(10): 3981-3990.
23. Solati M, Mahboobi HR. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients. J Nephropathol. 2012; 1(3): 123-125.
24. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigations. J Ren Inj Prev. 2013; 2(2): 61-65.
25. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011; 1(1): 3.